Articles On Resonance Health (ASX:RHT)
Title | Source | Codes | Date |
---|---|---|---|
Closing Bell: ASX hits all-time high as tech stocks lead broad rally
ASX hits record high with tech stocks leading TechnologyOne shares soar after strong earnings results Gold stocks rally as bullion rises above US$2600 The ASX surged to a new record on Monday, with technology and the other 10 sectors dr... |
Stockhead | RHT | 3 days ago |
Resonance Health expands clinical trial operations with Sun Pharmaceutical agreement
Australian healthcare technology and services company Resonance Health (ASX: RHT) has secured an agreement with Sun Pharmaceutical Industries to operate as its local Australian sponsor. As sponsor, Resonance will provide clinical research o... |
SmallCaps | RHT | 3 days ago |
Health Check: Sonic Healthcare is cashed up and ready to boom as earnings improve
Sonic reaffirms earnings guidance and says it is on the hunt for “sensible” acquisitions Boards face their inquisitors in peak AGM week Resonance shares soar on Sun Pharma deal Pathology and radiology giant Sonic Healthcare (ASX:SHL) sa... |
Stockhead | RHT | 3 days ago |
Guess which 2 ASX small-cap shares just rocketed 50% on big news!
Two ASX small-cap shares are shooting the lights out today, both posting intraday gains of more than 50%. One is a healthcare technology and services company. The other is a mineral exploration company. Which high-flying ASX small-cap share... |
Motley Fool | RHT | 3 days ago |
Closing Bell: Uranium stocks jump on Russia news; Resolute pays $160m to settle Mali dispute
ASX up as mining gains offset tech and bank losses Silex, Paladin and uranium stocks soar on supply squeeze Goldman cuts Aussie GDP forecast as US tariffs loom After a soft start to the day, the ASX bounced back and closed the day 0.3% ... |
Stockhead | RHT | 4 days ago |
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th... |
Stockhead | RHT | 2 weeks ago |
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Healthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as Fed cuts rates How ASX biotechs performed in the month of September The S&P 500 Health Care Index, a key world benchmark for health... |
Stockhead | RHT | 1 month ago |
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’
ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment The ASX Healthcare Index (AS... |
Stockhead | RHT | 2 months ago |
Closing Bell: Star Casino ruled unfit to reclaim licence; Cassius jumps 40pc as AustChina exits lithium deal
ASX 200 up on Friday boosted by strong US GDP and Wall Street gains Star Entertainment gets scathing remarks from regulator Downer EDI and TPG Telecom among the stocks to surge today The ASX closed 0.58% higher on Friday as investors di... |
Stockhead | RHT | 2 months ago |
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month
S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July The S&P/ASX 200 Health Care index [XHJ]... |
Stockhead | RHT | 3 months ago |
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners
The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month In a major blow for... |
Stockhead | RHT | 3 months ago |
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase... |
Stockhead | RHT | 4 months ago |
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month The S&P/ASX 200 Health Care [XHJ] closed flattish for the month o... |
Stockhead | RHT | 5 months ago |
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners
Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month The phrase ‘you are what you eat’ was coined almost a c... |
Stockhead | RHT | 6 months ago |
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | RHT | 6 months ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | RHT | 6 months ago |
Medtech Resonance Health expands global clinical trial reach with Perth-based TrialsWest acquisition
Medical technology firm Resonace Health is banking on its recent purchase of Perth-based TrialsWest to expand deeper into the global clinical trial industry. |
The West | RHT | 7 months ago |
Resonance Health to acquire TrialsWest in $8m deal, expands global clinical trial reach
Perth-based Resonance Health (ASX: RHT) has secured a deal to acquire private clinical trial site and research centre TrialsWest, representing a major step forward in its growth strategy. TrialsWest is one of Australia’s most experienced cl... |
smallcapsau.mystagingwebsite.com | RHT | 7 months ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | RHT | 8 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | RHT | 8 months ago |
Closing Bell: ASX ends it like Beckham… lower and with a pretty whimper, which could still suggest good things ahead
The ASX benchmark has closed slightly lower on Friday Losses across the Energy Sector weighed Small caps led ID8 The Aussie sharemarket has ended lower on Friday, driven to a small disgrace by the ongoing declines in oil prices – down... |
Stockhead | RHT | 1 year ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | RHT | 1 year ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | RHT | 1 year ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | RHT | 1 year ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | RHT | 1 year ago |
Resonance Health announces the appointment of chief financial officer
Resonance Health (ASX:RHT) has announced that Benjamin Carruthers has been appointed its chief financial officer and is expected to commence the role in October. |
BiotechDispatch | RHT | 1 year ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | RHT | 1 year ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | RHT | 1 year ago |
TMH Market Close: ASX200 finishes the week on a high
The ASX200 had a stronger session than expected, closing up, but only just. The real estate sector led the way gaining 1.8 per cent, utilities were also up by a per cent and materials just short of a per cent. In the green Goodman... |
themarketherald.com.au | RHT | 1 year ago |
In Case You Missed It: Resource tech snags the lead and a $1.55m BHP deal
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | RHT | 1 year ago |
TMH Spotlight: ASX edges higher, real estate leading gains
The ASX200 has gone against expectations and lifted ever so slightly by 0.1 of a per cent mid-session. Real estate led gainers – up nearly 1.5 per cent – but the heat was on communications and consumer discretionary which have both shed... |
themarketherald.com.au | RHT | 1 year ago |
ASX Health Stocks: Resonance Health jumps 22pc on global pharma contract
Resonance Health has been contracted by global pharma Sun Pharma New contract is worth $6.33m The Contract Research Organization (CRO) market is forecasted to grow rapidly Resonance Health (ASX:RHT), a company providing services to cli... |
Stockhead | RHT | 1 year ago |
Resonance Health (ASX:RHT) inks contract with major global pharma company
Resonance Health (RHT) is contracted by Sun Pharmaceutical Industries to provide services for its clinical trial in Australia RHT will provide clinical research organisation, laboratory analysis, and imaging services at various time poin... |
themarketherald.com.au | RHT | 1 year ago |
CLOSING BELL: Rock chips and Real Estate help keep the ASX fall to just 0.68pc for the day
The ASX grinds to a -0.68% close after another rough night on Wall Street. A late surge from the Real Estate sector saw it land on +1.11% for the day. Rock chip results dominated the Small Caps winners list – yep, it was that kinda day. ... |
Stockhead | RHT | 1 year ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | RHT | 1 year ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | RHT | 1 year ago |
ASX Health Stocks: Invex granted orphan drug designation in Europe; Resonance has a new CEO
Invex granted orphan drug designation in Europe Resonance Health has a new CEO EBR to raise $35m as it eyes market launch Invex Therapeutics (ASX:IXC) announced the granting of orphan drug designation (ODD) from the European Medicines A... |
Stockhead | RHT | 1 year ago |
ASX Today: Stocks to watch on Friday
Futures suggest the ASX will open lower to cap off the working week following a mixed session on Wall Street overnight. Meanwhile, oil prices plunged, sinking to below US$70 a barrel. On home soil, here are some ASX-listed companies w... |
themarketherald.com.au | RHT | 1 year ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | RHT | 1 year ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | RHT | 1 year ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | RHT | 1 year ago |
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week Earlier this week, Pfizer surprised the market by say... |
Stockhead | RHT | 1 year ago |
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?
The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit Medicare, telehealth and mental... |
Stockhead | RHT | 1 year ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | RHT | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | RHT | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | RHT | 1 year ago |
Closing Bell: Blocked! ACCC says no to TPG Telecom & Telstra deal
The ASX 200 rose a tidy 1.29% today with all sectors in the green ABS releases Aussie migrant data employment outcomes for the first time ACCC gives the thumbs down to Telstra and TPG’s merger plans The ASX 200 gained 1.29% today and... |
Stockhead | RHT | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | RHT | 1 year ago |
Resonance Health (ASX:RHT) contracted for two new clinical trials
Resonance Health (RHT) is contracted to provide services for two new clinical trials addressing iron-overload disordersThe company has signed contracts with two new pharmaceutical customers to provide FerriScan, Cardiac-T2, and related anal... |
themarketherald.com.au | RHT | 2 years ago |
ASX Health Stocks: Patent updates from Cynata and Proteomics; Ramsay sees good times ahead
Cynata gets Notice of Allowance from US Patent Office Proteomics secures patent in Hong Kong Ramsay Healthcare and Avita gave solid quarterly updates Cynata and Proteomics’ patents update Cynata Therapeutics (ASX:CYP) rose 8pc this mornin... |
Stockhead | RHT | 2 years ago |